Global /United States /Healthcare /Biotechnology /UPB

Upstream Bio, Inc.

UPB

• NASDAQ: UPB • Delayed

9.19USD -3.4%

As of 13 June 2026, Upstream Bio, Inc. has a market cap of $499.85M USD, ranking #15127 globally and #2637 in the United States. It ranks #1341 in the Healthcare sector, and #254 in the Biotechnology industry.

Global Rank

15127

Country Rank

2637

Sector Rank

1341

Industry Rank

254

Key Stats

Market Cap

$499.85MUSD

Enterprise Value

$159.88MUSD

Revenue (TTM)

$2.85MUSD

EBITDA (TTM)

-$160.17MUSD

Net Income (TTM)

-$143.44MUSD

PS Ratio

175.2

PB Ratio

1.5

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

E. Sutherland open_in_new

Employees

Founded

2021

IPO

11 Oct 2024

Website

upstreambio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3.4%	-4.7%	5.9%	-70%	-63%	-66%	4.6%	-72%	-72%

News

UPB Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	UPB Upstream Bio Inc ISIN: US91678A1079 Shares Out.: Shares Outstanding: 54.42M¹ Shares Float: 36.287M² TV: TradingView: NASDAQ: UPB SA: Stock Analysis: NASDAQ: UPB YF: Yahoo Finance: UPB GF: Google Finance: NASDAQ: UPB NQ: NASDAQ: UPB BA: Barron's: UPB MS: Morningstar: XNAS: UPB	9.19 USD	TV: TradingView: NASDAQ: UPB SA: Stock Analysis: NASDAQ: UPB YF: Yahoo Finance: UPB GF: Google Finance: NASDAQ: UPB NQ: NASDAQ: UPB BA: Barron's: UPB MS: Morningstar: XNAS: UPB

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Upstream Bio, Inc.

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 36K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 32K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 5K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 5K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 5K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 4K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 9K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 9K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 8K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 8K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 6K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 5K%	-	Germany

chevron_leftBack